MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

Merck & Co Inc.

Отворен

СекторЗдравеопазване

81.21 3.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

78.05

Максимум

82.45

Ключови измерители

By Trading Economics

Приходи

583M

3.7B

Продажби

-1B

16B

P/E

Средно за сектора

11.55

57.333

EPS

1.72

Дивидентна доходност

4.15

Марж на печалбата

23.963

Служители

73,000

EBITDA

1.3B

6.9B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+35.27% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.15%

2.63%

Следваща дата на дивидент

7.07.2025 г.

Следваща дата на екс-дивидент

16.06.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-56B

196B

Предишно отваряне

78.05

Предишно затваряне

81.21

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Merck & Co Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.04.2025 г., 18:18 ч. UTC

Значими двигатели на пазара

Pharma Shares Reverse Losses After Tariff Pause

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4.02.2025 г., 12:33 ч. UTC

Печалби

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4.02.2025 г., 11:57 ч. UTC

Печалби

Merck 4Q Sales Increase Results in Swing to Profit

24.04.2025 г., 20:08 ч. UTC

Печалби

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24.04.2025 г., 16:05 ч. UTC

Топ новини
Печалби

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24.04.2025 г., 14:36 ч. UTC

Пазарно говорене
Печалби

Merck's Challenges with Gardasil in China Continue -- Market Talk

24.04.2025 г., 14:10 ч. UTC

Пазарно говорене
Печалби

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24.04.2025 г., 11:35 ч. UTC

Печалби

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24.04.2025 г., 10:58 ч. UTC

Топ новини
Печалби

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24.04.2025 г., 10:55 ч. UTC

Печалби

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24.04.2025 г., 10:31 ч. UTC

Печалби

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Keytruda Sales $7.21B >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Keytruda Sales Up 4% >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24.04.2025 г., 10:30 ч. UTC

Печалби

Merck 1Q Januvia/Janumet Sales $796M >MRK

24.04.2025 г., 09:13 ч. UTC

Горещи акции

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24.03.2025 г., 05:00 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5.03.2025 г., 19:42 ч. UTC

Топ новини

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5.03.2025 г., 10:30 ч. UTC

Топ новини

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5.02.2025 г., 12:00 ч. UTC

Топ новини

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4.02.2025 г., 14:48 ч. UTC

Печалби

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4.02.2025 г., 11:51 ч. UTC

Печалби

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4.02.2025 г., 11:50 ч. UTC

Печалби

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Сравнение с други в отрасъла

Ценова промяна

Merck & Co Inc. Прогноза

Ценова цел

By TipRanks

35.27% нагоре

12-месечна прогноза

Среден 108 USD  35.27%

Висок 138 USD

Нисък 85 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Merck & Co Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

11

Купи

7

Задържане

0

Продай

Техническа оценка

By Trading Central

77.85 / 80.02Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.